{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/04/29/3283539/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-and-Breakthrough-Designation-for-Sovleplenib-for-the-Treatment-of-Warm-Antibody-Autoimmune-Hemolytic-Anemia.html", "message": "News view counter 688005 successfully enlarged"}